Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. - Wikidata - awgldk - TriplyDB

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

http://www.wikidata.org/entity/Q37861572

about

Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model.Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer Unusual presentation of mucinous adenocarcinoma in a post fistulectomy case.

P2860

Q34157162-50611735-F4A7-4369-9EFB-CB08A845C5ED Q34406719-94FFDDF4-4BF5-4DC4-AD80-D7120287FA91 Q35072438-99C8D0DF-1E86-4DCE-BE21-308B85F43F92 Q36043758-468CB3B9-2D78-4509-90E0-1CDAFCA64250 Q36102082-A0D4C0C8-CB3D-470F-87CC-9DD3A684BB15 Q42427335-406BFFC8-7EF3-4DAE-98EC-ADBC60810795

P2860

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

http://www.wikidata.org/entity/Q37861572

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@en

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@nl

type

label

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@en

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@nl

prefLabel

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@en

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@nl

P1433

Q37861572-7F793A23-4CA1-43FC-9EC8-5B9B7ACD1E01

P1476

Q37861572-2779C15A-96CA-4F71-B97E-28361561F5AF

P2093

Q37861572-0ABAB79A-1F01-4D03-A617-449B4E781F42

Q37861572-7982E328-E3E1-47AF-B260-29FD55EF77F9

Q37861572-B30B1D6B-A4DE-4BD8-914A-D8C5D0D31258

Q37861572-DEE38DBC-969F-4B36-80AF-5A870BBAFCB2

P2860

Q37861572-09AA56C3-1E8A-4DBF-A696-21AAA7B59ECA

Q37861572-11F902C0-92D5-4733-9EB8-524C3B4B5C76

Q37861572-2C033515-3571-4B1D-9830-7619A46C8D51

Q37861572-2F521053-2B46-40D9-ADA3-4F7EEAAD7DAB

Q37861572-33C3C0F5-5E21-42F1-A3DA-A05DF328DD9E

Q37861572-34D36C79-3BC3-43CB-A2A2-C9A58266041E

Q37861572-3DADEC16-B8EB-4C36-9FC9-A00E3BE7B124

Q37861572-4B89DAF3-DA3D-4E8F-A363-4702F8D27FBD

Q37861572-4C253392-6852-4B25-82DB-4C941805565A

Q37861572-5543E647-6E40-460F-9079-A52C3308B3A8

P2888

Q37861572-2E324EB7-6898-4E00-93A1-D0325D1F0351

P304

Q37861572-20F5E05C-3C55-4D33-932E-C9B53EC29E17

P31

Q37861572-0DF46214-0A66-48FF-9B50-467EC0004D3F

P356

Q37861572-624B465E-CCEE-4B86-97B9-C455196D914F

P433

Q37861572-B56B58E3-6508-4436-B12D-2B96401D8ACC

P478

Q37861572-444D19F5-407E-4B36-91B4-0A3D01E23AB6

P577

Q37861572-817E214A-33CB-436B-8224-4CC6F88D1474

P698

Q37861572-B1D379E9-D32A-4057-B2D6-093A8232E969

P356

S11912-011-0166-Z

P1433

Current Oncology Reports

P1476

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

@en

P2093

Brian Czito

http://www.w3.org/2001/XMLSchema#string

Christopher Willett

http://www.w3.org/2001/XMLSchema#string

Glen Balch

http://www.w3.org/2001/XMLSchema#string

Jeffrey Meyer

http://www.w3.org/2001/XMLSchema#string

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

Local excision of rectal cancer: what is the evidence?

Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Chemotherapy with preoperative radiotherapy in rectal cancer.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

P2888

s11912-011-0166-z

P304

177-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-011-0166-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21465120

http://www.w3.org/2001/XMLSchema#string